公司简介
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK...
关联新闻
- Vertex Pharmaceuticals Thrives on Higher Sales and Guidance
VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
- 7 healthcare stocks that stand out as investors pay up for the sector
Investors have pushed the healthcare sector to a record high, and some favored stocks have high projected revenue growth rates through 2028.
- Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
- Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
- Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
- Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
- Vertex raises annual revenue forecast on cystic fibrosis drugs strength
Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.